Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
New cell biology data from Europe shows simufilam interrupts a pathogenic signaling pathway in Alzheimer’s disease.Results corroborate prior research from other academic researchers.These data once...
-
New cell biology data from Europe shows simufilam interrupts a pathogenic signaling pathway in Alzheimer’s disease.Results corroborate prior research from other academic researchers.These data once...
-
AUSTIN, Texas, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that it...
-
Results of a randomized, controlled trial of oral simufilam in Alzheimer’s disease announced July 2023.Over 1,587 patients now enrolled in Phase 3 studies of simufilam in Alzheimer’s disease, an...
-
Simufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease.Drug Effects Favored Mild Alzheimer’s Disease.In Mild Alzheimer’s,...
-
Overactive mTOR Plays a Key Role in Aging and Alzheimer’s Disease.Simufilam Suppresses Overactive mTOR, Suggesting a Beneficial Drug Effect.Research is Published in Frontiers in Aging, a Peer-reviewed...
-
Publication Reviews Certain Receptor-Protein Interactions. Provides Overview of Basic Science Supporting Simufilam. Published in Drug Development Research, a Peer-Reviewed Journal. AUSTIN, Texas,...
-
AUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that its management has...
-
The Cognition Maintenance Study (CMS) is a 6-month, Randomized Controlled Trial of Simufilam in Over 125 Patients with Alzheimer’s Disease.Primary Outcome Measures Are Safety and Change in Cognition...
-
New in vitro data from Europe show that simufilam can reverse altered filamin A protein (FLNA) in pituitary tumor cells, leading to improved cell signaling.Data suggest FLNA is a central factor...